Black Diamond Therapeutics Publicizes Initial BDTX-1535 Dose Escalation Data Demonstrating Anti-Tumor Activity in Non-Small Cell Lung Cancer Patients

June 27, 2023

(24/7 MARKET NEWS) – Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) reported, this morning, initial clinical data from the dose escalation portion of the Phase 1 clinical study of BDTX-1535, an investigational fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor being developed for the treatment of non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM). The new data from the dose escalation portion of the Phase 1 study demonstrated clinical proof of activity of BDTX-1535 in NSCLC patients harboring both acquired resistance and intrinsic driver EGFR mutations.

Black Diamond Therapeutics is trading at $2.12, up $0.28 (+15.21%), on 37.14K premarket shares traded.

Its 52-week range is $1.18 to $4.08. This typically swings higher and lower and its next key inflection point is $2.55.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.